NCT03022682 Inflammation, Diabetes, Ethnicity and Obesity Cohort
| NCT ID | NCT03022682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Obesity |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2015-02 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2015-02 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obesity affects over one third of US adults (\>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time. In this proposed study, investigators will recruit participants from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.
Eligibility Criteria
Inclusion Criteria: * Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery. * Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort. Exclusion Criteria: * Participants with chronic kidney disease (\> stage 4) * Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.) * Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry * Clinically significant liver disease (e.g. Cirrhosis or liver failure) * Weight \> 450 pounds (DXA scan weight limit) * History of organ transplant * Treatment with chemotherapy or radiation therapy at the time of enrollment in study. * Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids) * Current nasal corticosteroid use (within the past month) * Excessive alcohol or substance abuse * Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months. * Patients actively enrolled in interventional trials involving investigational agents * Pregnant or breast-feeding women * Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee. * History of abnormal clotting * Previous bariatric surgery * Anticoagulant use * Methadone medication
Contact & Investigator
Suneil Koliwad, MD,PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT03022682 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03022682 currently recruiting?
Yes, NCT03022682 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of California, San Francisco to inquire about joining.
Where is the NCT03022682 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT03022682 clinical trial?
NCT03022682 is sponsored by University of California, San Francisco. The principal investigator is Suneil Koliwad, MD,PhD at University of California, San Francisco. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.